![]() |
Baricitinib
- 英文名称:Baricitinib
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B10985
- cas:1187594-09-7
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-05-23
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B10985 |
用途 | 科研检测 |
英文名称 | Baricitinib |
包装规格 | 1MG |
CAS编号 | 1187594-09-7 |
别名 | Baricitinib |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:98% by HPLC;NMR (Conforms)
分子式:C16H17N7O2S
分子量:371.42
溶剂:DMSO (30 mg/ml) DMF (50 mg/ml)
性状:White or off-white solid
存储:-20°C
Activity (short version):JAK 1/2 inhibitor
Function / Pharmacology:Baricitinib, approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50 = 5.9 nM) and 2 (5.7 nM), over 3 (0.56 μM).1 It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2 Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.3
分子式:C16H17N7O2S
分子量:371.42
溶剂:DMSO (30 mg/ml) DMF (50 mg/ml)
性状:White or off-white solid
存储:-20°C
Activity (short version):JAK 1/2 inhibitor
Function / Pharmacology:Baricitinib, approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50 = 5.9 nM) and 2 (5.7 nM), over 3 (0.56 μM).1 It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2 Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.3